

BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMIBUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI 400 001.
Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427 Tel.: 22618452/22661541, Tel/Fax: 22618327

12th August, 2022

To
The Bombay Stock Exchange Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001

Dear Sir/ Madam,

BSE SCRIP CODE: 524516

Name: Bacil Pharma Limited

Sub: Outcome of Board Meeting of the Company

This is to inform the exchange that the meeting of Board of Directors of the M/s. Bacil Pharma Limited has been duly convened on Friday, 12th day of August, 2022 through Video Conferencing. The Board transacted following items:

- Approved and adopted the un-audited Financial Results along with Limited Liability Report for the Quarter ended 30th June, 2022.
- Other Items with the permission of Board.

Please note that the Meeting of the Board of Directors commenced at 5:40 P.M. and concluded at 6:00 P.M.

Kindly take the note of the same and update on your records.

Thanking You,

For BACIL PHARMA LTD


Prakash Shah
Director
DIN: 01136800



BACIL PHARMA LIMITED

CIN : {L24200MH1987PLC043427}

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2022

(₹ in Lakhs)


Sr. No.	Particulars	Quarter ended			Year ended
		30/06/2022	31/03/2022	30/06/2021	31/03/2022
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from operations	-	-	-	-
	Other income	6.53	0.83	0.63	5.76
	Total revenue	6.53	0.83	0.63	5.76
2	Expenses				
	Employee benefits expense	2.06	2.12	1.35	6.00
	Depreciation and amortization expense	0.07	0.09	0.09	0.37
	Other expenses	2.16	372.27	1.56	385.39
	Total expenses	4.30	374.48	3.00	391.76
3	Profit before exceptional items and tax	2.23	(373.65)	(2.37)	(386.00)
	Exceptional items	-	-	-	-
	Profit / (Loss) from ordinary activities before tax	2.23	(373.65)	(2.37)	(386.00)
4	Tax expense:				
	Deferred tax	0.00	(0.01)	0.01	0.02
5	Profit/(Loss) from ordinary activities after tax	2.24	(373.66)	(2.36)	(385.98)
6	Other Comprehensive Income (OCI)				
	Item that will not be reclassified to profit or loss				
	Gain/(Loss) on recognised on fair valuation of Financial Assets	(10.14)	(23.01)	8.26	(0.26)
	Income tax relating to these items	2.64	6.00	(2.15)	0.07
	Total	(7.50)	(17.01)	6.11	(0.19)
	Reclassification of loss on asset held for sale	-	369.48	-	369.48
	Total Other Comprehensive Income (OCI)	(7.50)	352.47	6.11	369.29
	Profit/(Loss) for the Period	(5.27)	(21.19)	3.75	(16.69)
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	589.00	589.00	589.00	589.00
7	Earning Per Share (EPS) (Not annualised)				
	(1) Basic	0.04	(6.34)	(0.04)	(6.55)
	(2) Diluted	0.04	(6.34)	(0.04)	(6.55)

Notes:

- The Above Financial Results were reviewed by the audit committee of the board on 12th August 2022 and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditor have expressed on unmodified opinion. The review report has been filled with stock exchange and is available on the company's website. The Financial results have been prepared in accordance with Ind As notified under the companies (Accounting Standards) Rule 2015.
- Figures for the corresponding quarter ended i.e. 31st March 2022 in the previous year as reported in these financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the relevant financial year.
- The Company has single business segment therefore in the context of Ind As 108, disclosure of segment information is not applicable.
- Previous quarter figures have been regrouped /reclassified wherever necessary, to make them comparable.

FOR BACIL PHARMA LIMITED

Prakash Shah
Director
DIN: 01136800



Date: 12/08/2022
Place: Mumbai

Independent Auditor's Review Report on the Quarter Ended 30th June 2022 Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors
BACIL PHARMA LIMITED

1. We have reviewed the accompanying statement of unaudited financial results of BACIL PHARMA LIMITED (the "Company") for the quarter ended June 30, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Emphasis of Matter**


The recoverability of the balances of loans and advances given is yet to be determined by the management. These loans and advances are subject to confirmation by management. In absence of the confirmation, we are unable to comment on the same.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable Principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Laxmikant Kabra & Co LLP

Chartered Accountants

Firm Reg. No.: 117183W/ W100736



CA Siddhant Kabra

Partner

Membership No.: 193348



Place: Thane

Date: 12th August 2022

UDIN: 22193348AOWTFZ6433